CHENGDU, China, May 30, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced today that at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, the results of the Phase III clinical study OptiTROP-Lung05, evaluating the company's TROP2 ADC sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870)(佳泰莱^®) in combination with pembrolizumab (KEYTRUDA^®[1], MSD's anti-programmed cell death protein 1 (PD-1) antibody) as first-line treatment for Programmed Death-Ligand 1 (PD-L1) Tumor Proportion Score (TPS)≥1% non-small cell lung cancer (NSCLC), was presented as an oral presentation by Professor Caicun Zhou from Shanghai East Hospital, Tongji University (Abstract #8506, Lung Cancer – Metastatic Non-Small Cell).

Sac-TMT is designed with a unique, bifunctional linker and differentiated belotecan-derivative payload. The linker is conjugated via cysteine, which maximizes payload delivery to tumor cells both through its irreversible connection with the high-affinity and targeting anti-TROP2 monoclonal antibody sacituzumab and its pH-sensitive cleavage from a moderately toxic novel topoisomerase I inhibitor payload in the lysosome, with a drug-to-antibody-ratio (DAR) of 7.4.

In the OptiTROP-Lung05 study, a total of 413 patients were randomized (1:1) to receive either sac-TMT in combination with pembrolizumab or pembrolizumab monotherapy.

As of the data cutoff date (September 29, 2025), with a median follow‑up of 10.5 months, the study demonstrated that:

• Progression-free survival (PFS) showed statistically significant and clinically meaningful benefit in sac-TMT plus pembrolizumab compared with pembrolizumab alone. The median PFS assessed by blinded independent central review (BICR) was not reached (NR) vs 5.7 months (HR=0.35; 95% CI: 0.26-0.47; p<0.0001). The 12-month PFS rate was 62.4% vs 29.0%.

• Consistent benefit across prespecified subgroups: In patients with PD‑L1 TPS ≥50% and TPS 1–49%, the PFS HRs were 0.47 (95% CI: 0.29–0.77) and 0.28 (95% CI: 0.19–0.41), respectively. In patients with non‑squamous and squamous NSCLC, the PFS HRs were 0.28 (95% CI: 0.18–0.43) and 0.44 (95% CI: 0.29–0.66), respectively.

• Overall survival (OS) was not yet mature but showed a positive trend: median OS was NR vs 14.5 months (HR = 0.55; 95% CI: 0.36–0.85). The 12‑month OS rate was 80.4% vs 68.9%.

• The combination group showed improvements over pembrolizumab monotherapy group in objective response rate (ORR) (70.2% vs 42.0%), deep response rate (49.0% vs 25.9%), and 12-month duration of response rate (77.7% vs 59.4%).

The incidence of grade ≥3 treatment-emergent adverse events (TEAEs) was higher in the combination group, primarily driven by the expected hematologic adverse events of sac-TMT. Incidence of discontinuation of pembrolizumab due to TEAEs was similar in both groups. No sac-TMT-related deaths occurred. Adverse events of special interest (AEOSIs) were consistent with the known safety profiles of each individual agent, and no new safety signals were identified.

The interim analysis results show that sac-TMT plus pembrolizumab significantly prolonged PFS and reduced the risk of disease progression or death compared with pembrolizumab alone, with consistent PFS benefits observed across all prespecified subgroups (including PD‑L1 expression levels and histological subtypes). A positive trend in OS was also observed. Furthermore, the overall safety profile of sac-TMT in combination with pembrolizumab was manageable, consistent with the established safety profiles of sac-TMT alone or pembrolizumab alone.

Notably, the findings of OptiTROP-Lung05 have been simultaneously published in The Lancet（Impact Factor=88.5）, indicating that its clinical and academic value has received dual recognition from a leading international academic conference and an authoritative journal.

Professor Caicun Zhou, the national leading principal investigator from Shanghai East Hospital, Tongji University, said: "The positive results of the OptiTROP‑Lung05 study are encouraging. The study not only supports the application of sac‑TMT in an earlier-line setting for lung cancer, but also provides evidence of the 'ADC+IO' synergistic strategy being evaluated in the first-line setting for PD‑L1‑positive advanced NSCLC, potentially bringing a new option to a broad population of patients with lung cancer."

About sac-TMT(佳泰莱^®)

Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, breast cancer (BC), gastric cancer (GC), gynecological tumors and genitourinary tumors, among others. Sac-TMT is developed with a unique, bifunctional linker that maximizes payload delivery to tumor cells both through its irreversible connection with the anti-TROP2 monoclonal antibody sacituzumab and its pH-sensitive cleavage from a belotecan-derivative topoisomerase I inhibitor payload in the lysosome, with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases the payload KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells.

In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc, Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (which includes Mainland China, Hong Kong, Macao and Taiwan).

To date, four indications for sac-TMT have been approved and marketed in China for: 1) unresectable locally advanced or metastatic triple‑negative breast cancer (TNBC) who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting); 2) EGFR mutant-positive locally advanced or metastatic non-squamous NSCLC following progression on epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy and platinum-based chemotherapy; 3) epidermal growth factor receptor (EGFR) mutant-positive locally advanced or metastatic non-squamous NSCLC who progressed after treatment with EGFR-TKI therapy; 4) unresectable or metastatic hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) (Immunohistochemistry (IHC) 0, IHC 1+ or IHC 2+/In Situ Hybridization (ISH)-) BC who have received prior endocrine therapy and at least one line of chemotherapy in advanced setting. The first two indications above have been included in China's National Reimbursement Drug List (NRDL). This inclusion is expected to bring clinically meaningful benefits to a greater number of patients with BC and NSCLC. Additionally, sac-TMT has been granted six Breakthrough Therapy Designations (BTDs) by the National Medical Products Administration (NMPA).

Sac-TMT is the world's first TROP2 ADC drug approved for marketing in lung cancer. A new indication application for sac-TMT in combination with pembrolizumab (KEYTRUDA^®) as first‑line treatment for locally advanced or metastatic NSCLC who have PD-L1 TPS≥1% and are EGFR-negative and anaplastic lymphoma kinase (ALK)-negative has been accepted for review by the NMPA, and has entered the priority review and approval process. As of today, Kelun-Biotech has initiated 9 registrational clinical studies in China. MSD is evaluating 17 ongoing global Phase III clinical studies of sac-TMT as a monotherapy or in combination with pembrolizumab or other anti-cancer agents for several types of cancer. These studies are sponsored and led by MSD.

About Kelun-Biotech

Kelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical, which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. Kelun-Biotech focuses on major disease areas such as solid tumors, autoimmune, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. Kelun-Biotech is committed to becoming a leading global enterprise in the field of innovative drugs. At present, Kelun-Biotech has more than 30 ongoing key innovative drug projects, of which 4 projects with 8 indications have been approved for marketing, 1 project is in the NDA stage and more than 10 projects are in the clinical stage. Kelun-Biotech has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects with 5 indications approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit https://en.kelun-biotech.com/.

成都2026年5月30日 /美通社/ -- 2026年5月30日，四川科倫博泰生物醫藥股份有限公司(下稱「科倫博泰」或「公司」 6990.HK)宣佈，在美國芝加哥舉行的2026年美國臨床腫瘤學會(ASCO)年會上，同濟大學附屬東方醫院周彩存教授以口頭報告形式公佈了TROP2 ADC蘆康沙妥珠單抗(sac-TMT，亦稱SKB264/MK-2870)(佳泰萊^®)聯合帕博利珠單抗(可瑞達^®[1]，默沙東的抗程序性細胞死亡蛋白-1(PD-1)單抗)一線治療程序性細胞死亡配體1(PD-L1)腫瘤細胞陽性比例分數(TPS)≥1%非小細胞肺癌(NSCLC)的III期OptiTROP-Lung05研究結果(摘要編號#8506，肺癌-轉移性非小細胞)。

蘆康沙妥珠單抗(sac-TMT)採用獨特雙功能連接子以及基於貝洛替康衍生物的差異化有效載荷設計。其連接子通過半胱氨酸偶聯，一方面與具有高親和力及靶向效應的TROP2單抗沙妥珠單抗結合，另一方面在溶酶體中可從中等毒性新型拓撲異構酶I抑制劑有效載荷pH敏感裂解，最大限度將有效載荷遞送至腫瘤細胞，藥物抗體比(DAR)達到7.4。

在OptiTROP-Lung05研究中，共有413例患者被隨機(1:1)分配接受蘆康沙妥珠單抗(sac-TMT)聯合帕博利珠單抗或帕博利珠單抗單藥治療。

於數據截止時間(2025年9月29日)，中位隨訪10.5個月，研究數據顯示：

• 蘆康沙妥珠單抗(sac-TMT)聯合帕博利珠單抗組的無進展生存期(PFS)相較於帕博利珠單抗單藥組顯示出統計學意義和臨床意義的顯著改善。由盲態獨立中心評審(BICR)評估的中位PFS為尚未達到(NR) vs 5.7個月(HR=0.35; 95% CI: 0.26-0.47; p<0.0001)，12個月PFS率為62.4% vs 29.0%。

• 預設各亞組獲益一致：在PD-L1 TPS≥50%及TPS 1-49%患者中，PFS HR分別為0.47 (95% CI: 0.29-0.77)和0.28 (95% CI: 0.19-0.41)；在非鱗狀和鱗狀NSCLC患者中，PFS HR分別為0.28 (95% CI: 0.18-0.43)和0.44 (95% CI: 0.29-0.66)。

• 總生存期(OS)尚未成熟但顯示積極獲益趨勢：中位OS分別為NR vs 14.5個月(HR=0.55；95% CI: 0.36-0.85)；12個月OS率為80.4% vs 68.9%。
• 聯合治療組較帕博利珠單抗單藥組提高了客觀緩解率(ORR)(70.2% vs 42.0%)、深度緩解率(49.0% vs 25.9%) 及12個月持續緩解率(77.7% vs 59.4%)。

聯合治療組≥3級治療期間不良事件(TEAEs)發生率更高，主要是由蘆康沙妥珠單抗預期發生的血液學不良事件所致；兩組因TEAEs導致帕博利珠單抗永久停藥的發生率相似，未發生蘆康沙妥珠單抗相關的死亡；特別關注的不良事件(AEOSIs)與各試驗藥物已知的不良反應譜一致，未發現新的安全性信號。

期中分析結果表明，相較於帕博利珠單抗單藥，蘆康沙妥珠單抗(sac-TMT)聯合帕博利珠單抗可顯著延長PFS並降低疾病進展或死亡風險，且預設的各亞組中(包括PD-L1表達水平、組織學類型)均表現出一致的PFS獲益；同時已觀察到OS的獲益趨勢。聯合治療組整體安全性可控，且與蘆康沙妥珠單抗(sac-TMT)單藥或帕博利珠單抗單藥已建立的安全性特徵一致。

值得關注的是，OptiTROP‑Lung05研究成果已同步刊登國際頂刊《柳葉刀》（The Lancet, 影響因子IF=88.5），說明其臨床價值與學術價值已獲得國際一流學會及權威期刊的雙重認可。

全國牽頭主要研究者、同濟大學附屬東方醫院周彩存教授表示：「OptiTROP-Lung05研究取得的積極結果令人振奮。不僅為蘆康沙妥珠單抗在肺癌治療中的『應用前移』提供了循證證據，更率先驗證了『ADC+IO』協同策略在PD-L1陽性晚期NSCLC一線治療中的可行性，有望為廣大肺癌患者帶來全新的生存希望。」

關於蘆康沙妥珠單抗(sac-TMT)(佳泰萊^®)

作為公司的核心產品，蘆康沙妥珠單抗(sac-TMT)是一款公司擁有自主知識產權的新型TROP2 ADC，針對NSCLC、乳腺癌(BC)、胃癌(GC)、婦科腫瘤及泌尿生殖系統腫瘤等晚期實體瘤。蘆康沙妥珠單抗(sac-TMT)採用獨特雙功能連接子開發而成。該連接子一方面通過與抗TROP2單抗沙妥珠單抗形成不可逆結合，另一方面在溶酶體中可從貝洛替康衍生物拓撲異構酶I抑制劑有效載荷pH敏感裂解，從而最大限度將有效載荷遞送至腫瘤細胞，藥物抗體比(DAR)達到7.4。蘆康沙妥珠單抗(sac-TMT)通過重組抗TROP2人源化單克隆抗體特異性識別腫瘤細胞表面的TROP2，其後被腫瘤細胞內吞併於細胞內釋放有效載荷KL610023。KL610023作為拓撲異構酶I抑制劑，可誘導腫瘤細胞DNA損傷，進而導致細胞週期阻滯及細胞凋亡。此外，其亦於腫瘤微環境中釋放KL610023。鑒於KL610023具有細胞膜滲透性，其可實現旁觀者效應，即殺死鄰近的腫瘤細胞。

於2022年5月，公司授予默沙東(美國新澤西州羅威市默克公司的商號)在大中華區(包括中國內地、香港、澳門及台灣)以外的所有地區開發、使用、製造及商業化蘆康沙妥珠單抗(sac-TMT)的獨家權利。

截至目前，蘆康沙妥珠單抗(sac-TMT)的4項適應症已於中國獲批上市，分別用於：1)既往至少接受過2種系統治療（其中至少1種治療針對晚期或轉移性階段）的不可切除的局部晚期或轉移性三陰性乳腺癌(TNBC)；2)經表皮生長因子受體-酪氨酸激酶抑制劑(EGFR-TKI)和含鉑化療治療後進展的表皮生長因子受體(EGFR)基因突變陽性的局部晚期或轉移性非鱗狀NSCLC；3)經EGFR-TKI治療後進展的EGFR基因突變陽性的局部晚期或轉移性非鱗狀NSCLC；4)既往接受過內分泌治療且在晚期疾病階段接受過至少一線化療的不可切除或轉移性的激素受體陽性(HR+)且人類表皮生長因子受體2陰性(HER2-) (免疫組織化學(IHC) 0、IHC 1+或IHC 2+/原位雜交(ISH)-) BC；其中前2項適應症已經被納入醫保範圍，將為更多乳腺癌和非小細胞肺癌患者帶來臨床獲益。此外，蘆康沙妥珠單抗(sac-TMT)已獲國家藥品監督管理局(NMPA)授予6項突破性療法認定(BTD)。

蘆康沙妥珠單抗(sac-TMT)是全球首個在肺癌適應症獲批上市的TROP2 ADC藥物。蘆康沙妥珠單抗(sac-TMT)用於聯合帕博利珠單抗(可瑞達^®)一線治療PD-L1腫瘤比例分數(TPS)≥1%的EGFR基因突變陰性和間變性淋巴瘤激酶(ALK)陰性的局部晚期或轉移性NSCLC的新增適應症上市申請已獲NMPA受理，並被納入優先審評審批程序。目前，科倫博泰已在中國開展9項註冊性臨床研究。默沙東已啟動17項正在進行的蘆康沙妥珠單抗(sac-TMT)作為單藥療法或聯合帕博利珠單抗或其他抗癌藥物用於多種類型癌症的全球性III期臨床研究(這些研究由默沙東申辦並主導)。

關於科倫博泰

四川科倫博泰生物醫藥股份有限公司(簡稱「科倫博泰」，股票代碼：6990.HK)是科倫藥業控股子公司，專注於創新生物技術藥物及小分子藥物的研發、生產、商業化及國際合作。公司圍繞全球和中國未滿足的臨床需求，重點佈局腫瘤、自身免疫和代謝等重大疾病領域，建設國際化藥物研發與產業化平台，致力於成為在創新藥物領域國際領先的企業。公司目前擁有30餘個重點創新藥項目，其中4個項目8個適應症已獲批上市，1個項目處於NDA階段，10餘個項目正處於臨床階段。公司成功構建了享譽國際的專有ADC及新型偶聯藥物平台OptiDC^TM，已有2個ADC項目5個適應症獲批上市，多個ADC或新型偶聯藥物產品處於臨床或臨床前研究階段。更多信息請訪問官網https://kelun-biotech.com/。

成都2026年5月30日 /美通社/ -- 2026年5月30日，四川科倫博泰生物醫藥股份有限公司(下稱「科倫博泰」或「公司」，6990.HK)宣佈，在美國芝加哥舉行的2026年美國臨床腫瘤學會(ASCO)年會上，廣東省人民醫院周清教授以口頭報告形式公佈了新一代選擇性轉染過程中重排(RET)抑制劑富馬酸侖博替尼(A400/EP0031，寧泰萊^®[1])用於治療晚期RET融合陽性非小細胞肺癌(NSCLC)的關鍵II期研究結果(摘要編號#8505，肺癌—轉移性非小細胞)。基於此項研究結果，富馬酸侖博替尼用於治療RET融合陽性的局部晚期或轉移性NSCLC成人患者的新藥上市申請(NDA)已獲中國國家藥品監督管理局(NMPA)受理。

該研究共納入71例既往接受過含鉑化療及免疫治療的患者(經治患者)及92例既往未接受過系統治療的患者(初治患者)，截至2025年10月29日，中位隨訪時間為22.6個月和20.7個月。

經獨立審查委員會(IRC)確認的ORR在初治患者中為81.3%(95% CI: 71.8-88.7) ，在經治患者中為87.1%(95% CI: 77.0-93.9)。

在初治患者中，中位持續緩解時間(mDOR)與中位無進展生存期(mPFS)均未達到；在經治患者中，mDOR為25.7個月，mPFS為27.5個月。

在40例基線存在中樞神經系統(CNS)轉移的患者中(根據神經腫瘤學腦轉移瘤反應評估(RANO-BM)標準進行IRC評估)，顱內完全緩解(CR)為30%，疾病控制率(DCR)為92.5%(95% CI: 79.6–98.4)。

安全性方面，富馬酸侖博替尼耐受性良好，治療相關不良事件(TRAEs)主要為1-2級。因治療相關不良事件導致的停藥率為1.2%，未報告治療相關死亡事件。

研究表明，富馬酸侖博替尼在RET融合陽性NSCLC中展現出強勁且持久的臨床療效，無論治療線數如何，其療效在總體預後較差的患者人群中均得到驗證。在基線存在可測量CNS轉移的患者中，亦觀察到較好的CNS療效。整體安全性可控，未出現新的安全性信號。

主要研究者廣東省人民醫院周清教授表示：「從2023年ASCO首次報告Ⅰ期研究，到今天公佈關鍵Ⅱ期結果，我們見證了富馬酸侖博替尼從早期探索到確證性研究的紮實進階。關鍵Ⅱ期研究顯示，無論在初治還是經治的RET融合陽性NSCLC患者，富馬酸侖博替尼均能帶來深度且持久的緩解，尤其在基線CNS轉移患者中展現出卓越的顱內療效。作為新一代選擇性RET抑制劑，其有望為患者提供重要的治療新選擇。」

關於富馬酸侖博替尼(A400/EP0031，寧泰萊^® )

富馬酸侖博替尼是一款新型新一代選擇性RET抑制劑，開發用於治療NSCLC、甲狀腺髓樣瘤(MTC)以及其他RET變異的實體瘤。富馬酸侖博替尼用於治療RET融合陽性的局部晚期或轉移性NSCLC成人患者的NDA已獲NMPA受理。公司亦在中國進行一項其用於治療RET+實體瘤的Ib/II期臨床研究。

2021年3月，本公司向總部設在英國的國際腫瘤藥物開發公司Ellipses Pharma Limited授出在大中華區及部分亞洲國家之外開發、製造及商業化此藥物的獨家授權。2024年4月，富馬酸侖博替尼獲美國食品藥品監督管理局(FDA)批准進入II期臨床研究(NCT05443126)，目前正在美國、英國、歐盟和阿聯酋入組患者，評估該藥物作為單藥及聯合化療在RET融合陽性晚期NSCLC中的療效。

關於科倫博泰

四川科倫博泰生物醫藥股份有限公司(簡稱「科倫博泰」，股票代碼：6990.HK)是科倫藥業控股子公司，專注於創新生物技術藥物及小分子藥物的研發、生產、商業化及國際合作。公司圍繞全球和中國未滿足的臨床需求，重點佈局腫瘤、自身免疫和代謝等重大疾病領域，建設國際化藥物研發與產業化平台，致力於成為在創新藥物領域國際領先的企業。公司目前擁有30餘個重點創新藥項目，其中4個項目8個適應症已獲批上市，1個項目處於NDA階段，10餘個項目正處於臨床階段。公司成功構建了享譽國際的專有ADC及新型偶聯藥物平台OptiDC^TM，已有2個ADC項目5個適應症獲批上市，多個ADC或新型偶聯藥物產品處於臨床或臨床前研究階段。更多信息請訪問官網https://kelun-biotech.com/。

BOSTON, May 29, 2026 /PRNewswire/ -- XtalPi (2228.HK), an AI- and robotics- powered drug discovery platform, announced that its strategic collaboration with innovative biopharmaceutical company DoveTree Medicines Unus Inc. has achieved substantial progress, and that XtalPi has received the second payment under the agreement.

Since the two parties entered into a collaboration in June 2025 with a total possible aggregate value of up to US $5.99 billion if resulting in an approved product directed to each of the targets of interest to DoveTree, the partnership has made significant progress. All patents related to the pipeline from the initial upfront payment of US$51 million have now been fully transferred to DoveTree. One preclinical candidate (PCC) has advanced into IND-enabling studies. According to the agreement, XtalPi has now received the second payment of US$19 million. The two parties will further deepen discovery collaboration with agreed priorities and continuously accelerate translation from discovery to clinical development.

XtalPi's proprietary dynamic conformation precision modeling platform uses quantum physics algorithms and AI-driven multiscale molecular simulations as dual engines. Rather than relying on static crystal structures, it simulates more complete processes of a target protein's conformational dynamics in a physiologically relevant environment at atomic-level precision. This allows the platform to accurately capture transiently exposed allosteric sites and PPI interfaces that traditional methods often miss, providing high-resolution structural insights that guide molecular design with both speed and accuracy.

Meanwhile, XtalPi's integrated drug discovery platform—combining AI, physics-based design, and automation-driven synthesis and optimization—seamlessly connects molecular virtual screening with physical synthesis, accelerating the feedback loop between design and validation. Based on structural information generated by the dynamic conformation model, XtalPi has established predictive models for protein complexes used in hit compound screening, enabling highly efficient virtual screening. High-potential molecules with superior drug-like properties are then evaluated for synthesizability and synthetic routes by the company's proprietary SureRXN reaction prediction model, after which a fleet of automated robotic workstations conduct parallel synthesis and activity testing, forming a high-throughput closed-loop iteration of "Design–Make–Test–Analyze" (DMTA).

This system can synthesize and test 3,000–4,000 novel molecules within 2–3 months, with a synthesis success rate consistently above 80%. Even when facing entirely new targets with extremely limited prior data, the platform can rapidly accumulate high-quality empirical data within a very short timeframe, continuously driving algorithm optimization and molecular evolution. This end-to-end capability — from mechanistic insight to physical delivery — brings historically intractable targets onto a significantly de-risked preclinical development trajectory, with the potential to accelerate their transformation into clinically actionable assets.

The momentum of the XtalPi–DoveTree collaboration programs is built on the strengths of both partners: DoveTree brings deep expertise in target biology, translational medicine, and modality innovation, while XtalPi is redefining the efficiency and scalability of molecular discovery through AI and automation.

The combined strengths of the two companies not only enable new drug discovery programs to advance rapidly from initiation to the clinic, but also ensure that these programs address high unmet medical needs by tackling highly validated, difficult-to-drug targets with clear paths to clinical translation and commercialization.

XtalPi is eligible to receive future milestones and royalties, allowing the long-term value of its AI platform to be realized through pipeline expansion and advancement.

Dr. Gregory Verdine, Founder and CEO of DoveTree, stated:

"XtalPi has built an impressive platform operating at the convergence of AI, physics-based molecular design, and automation-driven synthesis and optimization. These integrated capabilities have the potential to improve both the speed and quality of discovery efforts against challenging biological targets. We are pleased with the progress of the collaboration to date and look forward to advancing additional programs toward clinical development."

Dr. Wen Shuhao, Chairman of XtalPi, stated:

"Our collaboration with DoveTree continues to generate verifiable results. This not only validates the advantages of our technological pathway, but also gives us strong conviction as we scale the pipeline. XtalPi has already established a complete closed loop from target discovery to PCC across multiple real-world R&D projects. Our focus now is on systematically extending this approach to a broader set of high-value targets, delivering innovation with a higher probability of success for the industry, and pushing the boundaries of what can be achieved in drug discovery."

About DoveTree Medicines

DoveTree is an innovative biopharmaceutical company focused on developing first-in-class therapies for diseases with significant unmet clinical needs. The company was founded and is led by scientist and entrepreneur Dr. Gregory Verdine, and leverages deep insights into biology together with advanced artificial intelligence technologies to explore novel therapeutic approaches and accelerate the development of transformative medicines. DoveTree is named after the Davidia involucrata — also known as the Dove Tree — a rare ancient plant native to Yunnan, China. The company integrates the frontier R&D innovation and mature pharmaceutical market of the United States with China's rapidly emerging R&D ecosystem and innovative pipeline assets, like the beautiful and flourishing "Dove Tree," bringing new hope to human health.

About XtalPi

XtalPi Holdings Limited ("XtalPi," HKEX: 2228) was founded in 2015 by physicists from the Massachusetts Institute of Technology (MIT). The company is a technology platform focused on quantum physics–based and AI-driven innovation in drug and materials discovery. By integrating quantum physics, artificial intelligence, cloud computing, and large-scale automation, XtalPi provides research and development solutions and services to global pharmaceutical, materials science, consumer products, energy, and advanced chemicals industries.

XIAMEN, China, May 29, 2026 /PRNewswire/ -- In recent years, the global athletic footwear market has maintained steady sales volume growth. This expansion is driven by the escalating consumer demand for superior comfort, advanced functionality, and everyday versatility, coupled with technological breakthroughs in midsole materials and manufacturing processes toward high performance, lightweight structures, and sustainability. Concretely, global athletic footwear sales volume has expanded from 4.57 billion pairs in 2021 to 5.30 billion pairs in 2025. In the Chinese market*, the growing popularity of marathons and road running events among the general public has further catalyzed the expansion of the professional racing shoes and related running gear segments. Against this backdrop, Xtep has distinguished itself with market leadership that has been independently validated.

Based on independent market research conducted by Frost & Sullivan on the global and Chinese running shoes and sportswear industries, Xtep has been awarded three prestigious market leadership recognitions: " Leading Position in global running shoes market based on sales volume in 2025."; " Ranked No.1 in China by Marathon Running Shoes Wearing Rate for 3 consecutive years（2023-2025）"; and " Ranked Top 3 among Chinese Sportswear brands. (Measured by Sales value of 2025)." From the scale of event sponsorships and depth of runner services to on-track product performance, Xtep's comprehensive cultivation in the running domain has received definitive validation from international authoritative research institutions and the global market. To understand how Xtep achieved these milestones, it is essential to first examine the broader running shoe industry—its product categories, evolution, and current market drivers.

Running Shoe Market: An Overview

Running shoes are purposefully designed athletic footwear engineered to deliver superior cushioning, support, stability, and breathability. Their core value proposition lies in joint protection, running efficiency enhancement, and multi-scenario adaptability. Categorized by function, the market comprises stability, racing, and cushioned running shoes; based on application scenarios, the product portfolio is divided into road running shoes, treadmill and indoor athletic shoes, and trail running shoes.

The global running shoe industry has evolved through three distinct epochs: the Performance-Oriented Era (Pre-1980s–2000), during which products primarily served competitive sports with a core focus on functional enhancements; the Technological Iteration & Mass Expansion Era (2000–2015), characterized by major upgrades in core technologies such as cushioning, support, and lightweight engineering, alongside the popularization of running among the general fitness public; and the Segmented Scenarios & Brand Premiumization Era (2020–Present), where consumer preferences have shifted toward specialized niches and platform-based technological innovations, steering the industry toward high performance, multi-scenario utility, and strategic brand differentiation.

Echoing global megatrends, China's running shoe industry has undergone a parallel upgrade from rudimentary features to specialization, scenario-specific design, and robust brand positioning. Since 2000, international brands have accelerated their market entry into China, while domestic powerhouses such as Xtep, Anta, and Li-Ning have steadily risen, propelling the Chinese running shoe market into its own era of technological iteration and mass-market expansion.

Market Drivers of the Running Shoe Industry

Driven by the widespread adoption of healthy lifestyles and the continuous momentum of marathons and road running events, market demand within the running shoe industry has been continuously unleashed. In 2024, a total of 749 road running races were hosted nationwide, drawing a cumulative total of over 7.04 million participants. In 2025, the racing landscape pivoted toward optimizing quality while rationalizing quantity, with 594 events held throughout the year, attracting 6.399 million participants. The mainstream popularization of these events has significantly expanded the runner baseline, thereby generating sustainable growth in demand for professional running shoes, functional apparel, and supporting gear.

The competitive landscape of the running shoe industry is pivoting from basic functionalities to a holistic competition encompasses technological platforms, product matrices, and multi-scenario adaptability. As marathons serve as a crucial testing ground for the product capabilities of professional footwear, domestic running shoes have seen a continuous surge in their wearing rate, brand exposure, and word-of-mouth reputation on the race tracks in recent years. An increasing number of runners are opting for domestic professional running shoes for both daily training and competitive races, underscoring the growing market endorsement of domestic brands regarding racing performance, wearing experience, and product stability.

Xtep Builds a Comprehensive Professional Running Ecosystem to Fully Meet the Needs of Both Elite and Mass Runners

Since establishing its strategic focus on running in 2007, Xtep has consistently deepened its footprint in the running track. Driven by technological R&D, oriented by runner needs, and supported by professional services, Xtep has constructed an industry-leading professional running ecosystem characterized by all-scenario coverage and all-population adaptability, cementing its status as a premier brand in China's running domain. Adhering to innovation-driven and independent R&D, Xtep has consolidated four core running technologies: XTEP FIT Technology, which leverages over 300,000 Chinese foot shape data points to establish China's largest foot shape database, crafting shoe lasts tailored to the Chinese populace; XTEP DURA Technology, which pioneers the use of marathon-grade CPU materials coupled with AI gait analysis to design outsole patterns, achieving a wear-resistant and anti-slip lifespan of over 2,000 kilometers; XTEP ACE+ Technology, which utilizes a supercritical foaming process with a dual-density "soft upper, resilient lower" golden combination design, delivering an outstanding resilient and elastic underfoot feel to help runners accelerate; and Xtep's proprietary XTEP POWER Technology Matrix, which innovatively applies aerospace-grade PI fibers and basalt fibers to running shoes, effectively resolving the industry pain point of carbon fiber brittleness and fracture, thereby providing runners with more powerful propulsion and long-lasting stability. These four technological platforms act synergistically to form the technical bedrock of Xtep's professional running footwear.

In terms of product matrix, Xtep centers on its flagship "Champion Edition Collection" to build a comprehensive running shoe portfolio spanning elite racing, progressive training, and mass jogging. Among them, the 160X Champion Edition series has undergone multiple generations of iterations. As of 2025, it has empowered 141 Chinese athletes to clinch 620 marathon championships, becoming one of the most iconic domestic racing shoes on the marathon circuit. On March 1, 2026, at the Tokyo Marathon, Xtep's running brand ambassador, Feng Peiyou, wearing the Xtep 160X 7.0 PRO in the "Champion Sonata" colorway, shattered the national men's marathon record with a time of 2 hours, 05 minutes, and 58 seconds, ushering Chinese marathons into the "2:05 Era." Concurrently, models such as the 360X (the world's first flexible carbon plate running shoe), the 260X (an all-around competitive training powerhouse), and the AirFlow (a flagship cushioned running shoe) collectively form a comprehensive product lineup covering everyone from elite racers to mass fitness enthusiasts. Notably, Xtep running shoes have secured the No.1 ranking in China by Marathon Running Shoes Wearing Rate for 3 consecutive years（2023-2025）*.

Furthermore, Xtep continues to champion China's road running cause, having sponsored over 1,000 marathon events nationwide, making it the brand with the highest number of marathon sponsorships in China. Xtep has established 71 running clubs, serving over 2.5 million "Xtep Runners" members. Concurrently, through its proprietary IPs such as the "Chinese Running Race & Mass Running" initiative (jointly launched with the Chinese Athletics Association since 2019) and the "321 Running Festival," Xtep has constructed a one-stop runner service ecosystem encompassing professional gear, training courses, community activities, and event services.

1. Sourced from Frost & Sullivan's 2025 Independent Global Running Shoes Market Research Report.

2. Sourced from Frost & Sullivan's 2025 Independent China Marathon Market Research Report.

CHANGSHA, China, May 29, 2026 /PRNewswire/ -- Zoomlion is accelerating the global rollout of new energy and intelligent agricultural machinery, using major exhibitions in Turkey, South Africa, Thailand, Brazil, and China to showcase hybrid tractors, intelligent harvesters and crop-specific mechanization solutions aligned with agriculture's shift toward greener, smarter, and more mechanized operations.

Hybrid tractors emerged as the Company's key showcase products across multiple markets. The DV3504 and DQ2604 featured prominently in Turkey and South Africa which highlighted Zoomlion's push to position hybrid machinery as a practical solution for large-scale farming and lower fuel consumption. In Turkey, the tractors made their full debut at the Konya Agriculture Fair, where Zoomlion emphasized their performance in high-load applications such as deep tillage, supported by its self-developed MiDD distributed intelligent electric drive system and dynamic energy control technology. In South Africa, the DV3504 became a centerpiece of the Company's presentation at the Nampo show, which drew interest for its combination of power, intelligent operation and energy-saving performance.

Brazil marked another milestone, with Zoomlion making its first appearance at Agrishow and formally launching the DV3504 for the local market. The Company positioned the tractor around Brazil's green agriculture trend and the operating needs of large-scale soybean and corn farming, while also signaling further regional investment through its local subsidiary and manufacturing base.

Beyond tractors, Zoomlion is using localized solutions to address crop-specific mechanization needs. At AGRITECHNICA ASIA 2026 in Bangkok, the Company launched the C600 sugarcane combine harvester as part of a broader solution for Southeast Asia's sugarcane sector. Designed for Thailand's planting density and terrain, the C600 integrates harvesting, conveying, defoliation, and cleaning, while its Z-Pilot intelligent management system incorporates autonomous driving and intelligent scheduling technologies. Zoomlion also presented supporting tractors and implements to form a full-process sugarcane mechanization solution.

At the Xinjiang International Agricultural Machinery Expo, Zoomlion further underscored the role of intelligent new energy technologies in its upgrade strategy. The Company introduced nine hybrid products, including the DH7-6000, which it described as the world's first tandem hybrid grain combine harvester. According to Zoomlion, the machine delivers lower energy consumption and higher operating efficiency than conventional equipment.

Taken together, the exhibitions show how Zoomlion is linking hybrid and intelligent technology with more localized agricultural solutions, while continuing to advance its "high-end, international, new energy" strategy in global markets.

The Intelligent Driving 9.0 version powered by LI AUTO-W (02015.HK)'s self-developed Mahe M100 chip achieved a major upgrade compared with version 8.0, Xie Yan, Chief Technology Officer of LI AUTO-W (02015.HK), said. Version 9.0 is the first intelligent driving system fully running on the Group's in-house chip. It is ranked among the first tier in the highly competitive industry, though this marks only the beginning, the CTO said. The Group aims in 2H26 to benchmark its performance against Tesla, Inc. (TSLA.US) FSD Beta version 14.

On international expansion, President Ma Donghui said LI AUTO-W's globalisation strategy is progressing steadily. In overseas markets, the Group is adopting a phased expansion approach, flexibly choosing between establishing subsidiaries to develop dealer networks or appointing exclusive general distributors based on local market size and competitive landscape. It aims to leverage leading local partners to rapidly build an integrated service system covering sales, delivery and after-sales support.

Ma added that LI AUTO-W's brand and products continue to gain recognition in overseas markets. In the Middle East and Central Asia markets, the L-series extended-range models will serve as the main offerings, with official entry into these markets in 3Q26. In 2H26, the Group will also launch the all-electric I6 model in the European market. For right-hand-drive markets, a right-hand-drive version of the Mega will be introduced by the end of this year in core Asia-Pacific regions such as Hong Kong and Singapore.
~

AASTOCKS Financial News
Website: www.aastocks.com

LG Electronics announced the launch of a series of innovative automotive products built on Google technology, sending its shares up by as much as 27% today (29th).

LG Electronics said its new suite of solutions is based on the Android Automotive operating system, featuring a single-chip design capable of simultaneously controlling multiple displays of different sizes, distinguishing it from traditional in-vehicle systems.

The company noted that the solution helps automakers sharply reduce the cost of deploying multi-screen in-car systems.
~

AASTOCKS Financial News
Website: www.aastocks.com

Jensen Huang, Founder and CEO of NVIDIA Corporation (NVDA.US), will attend NVIDIA's annual AI developer conference, GTC Taipei 2026, in Taipei next week, and will visit South Korea after completing his main itinerary, report told.

Industry sources expected that Huang may discuss cooperation during his visit to South Korea in areas such as high-bandwidth memory (HBM), next-generation AI accelerators and wafer foundry services with major South Korean semiconductor companies including Samsung Electronics and SK Hynix.
~

AASTOCKS Financial News
Website: www.aastocks.com

深圳2026年5月29日 /美通社/ -- 全球領先的AI+機器人藥物研發平台企業晶泰科技（2228.HK）今日宣佈，與創新生物製藥公司 DoveTree Medicines Unus Inc. 的戰略合作取得重要進展，並收到第二筆付款。

自去年6月雙方達成總價值最高可達59.9億美元的合作協議以來，雙方協作持續取得顯著進展。此前5100萬美元首付款所涉管線的相關專利已全部轉讓至 DoveTree。其中一個臨床前候選分子（Pre-clinical candidate, PCC）已率先推進至臨床申請前準備（IND-enabling）研究階段。根據協議，晶泰科技已收到第二筆1900萬美元付款。雙方未來將圍繞既定重點方向進一步深化藥物發現合作，並持續加速項目從早期發現向臨床開發的轉化。

重塑靶向策略：從「不可成藥」到系統性干預

此次合作結合了 DoveTree 在靶點生物學與轉化醫學方面的專業能力，以及晶泰科技在計算與自動化賦能藥物發現方面的平台能力。

晶泰科技獨有的動態構象精準建模平台，以量子物理算法與AI多尺度分子模擬為雙重引擎，能夠超越晶體結構靜態「快照」的局限，在原子精度下模擬真實生理環境中靶點蛋白更完整的運動過程，實現構象機制洞察精度與效率的雙重躍升。

與此同時，晶泰科技融合量子物理、AI 以及自動化合成與測試能力的 AI 藥物研發平台，實現了分子虛擬篩選與物理合成之間的高效銜接，加速了分子設計與驗證之間的反饋閉環。根據動態構象模型提供的結構信息，晶泰科技已構建起用於命中化合物（Hit）篩選的蛋白複合物預測模型，實現高效的 AI 虛擬篩選。具有潛力的分子隨即由晶泰自研的  SureRXN 反應預測模型精確評估可合成性、預測合成路徑，再交由大規模自動化機器人實驗集群完成並行合成與活性測試，形成「設計—合成—測試—分析」（DMTA）的高通量迭代閉環。

這一體系可在2-3個月內完成3000-4000個全新分子的合成與測試，成功率穩定超過 80%。即便面對缺乏先驗數據的全新靶點，平台也能在短時間內積累起高質量的真實數據，持續驅動算法優化與分子進化。這種從機制研究到實驗交付的能力，有望推動過去難以觸達的「難成藥」靶點進入更具可預測性的臨床前開發軌道，並加速其轉化為具有臨床價值的項目資產。

強強聯合，雙向賦能

晶泰科技與 DoveTree 合作項目的快速推進，建立在雙方優勢能力的互補之上：DoveTree 在靶點生物學、轉化醫學以及治療模式創新方面具備深厚積累，而晶泰科技則通過 AI 與自動化技術提升分子發現的效率與規模化能力。

雙方優勢的結合，不僅能夠推動新藥研發項目從發現階段更快進入臨床開發，同時也聚焦於具有明確臨床轉化潛力、但傳統上難以成藥的重要靶點，從而更有效地滿足重大未滿足醫療需求。

根據合作協議，晶泰科技未來有資格獲得後續里程碑付款及銷售分成，使其 AI 平台的長期價值能夠伴隨項目推進而持續體現。

晶泰科技董事局主席溫書豪博士表示：「我們與 DoveTree 的合作正持續取得可驗證的成果。這不僅印證了我們技術路徑的優勢，也讓我們對後續管線的規模化推進充滿信心。晶泰科技已經在多個研發項目的實戰中跑通了從靶點到 PCC 的完整閉環，我們期待將這一模式系統性地拓展到更多高價值靶點上，為行業提供確定性更高的創新產出，不斷突破『可成藥』的邊界。」

DoveTree 創始人 Gregory Verdine 教授表示：「晶泰科技打造了一個令人印象深刻的平台，其能力建立在 AI、基於物理的分子設計以及自動化合成與優化的深度融合之上。這些一體化能力有望同時提升針對複雜生物靶點開展藥物發現的速度與質量。我們對目前合作取得的進展感到滿意，並期待推動更多項目邁向臨床開發階段。」

關於DoveTree Medicines

DoveTree 是一家創新生物製藥公司，專注於開發針對重大未滿足臨床需求疾病的首創新藥（first-in-class）療法。公司由科學家及企業家 Gregory Verdine 博士創立並領導，結合對生物學機制的深刻理解與先進人工智能技術，探索新型治療策略並加速變革性藥物的開發。DoveTree 以中國雲南特有的古老珍稀植物——珙桐（又稱「鴿子樹」）命名。公司致力於融合美國前沿研發創新能力與成熟醫藥市場，以及中國快速崛起的研發生態與創新管線資源，如同繁盛而美麗的「鴿子樹」一樣，為人類健康帶來新的希望。

關於晶泰科技

晶泰科技（"XtalPi Holdings Limited"，股份簡稱：晶泰控股，XTALPI，股票代碼：2228.HK）由三位麻省理工學院的物理學家於 2015 年創立，是一個基於量子物理、以人工智能賦能和機器人驅動的創新型研發平台。公司採用基於量子物理的第一性原理計算、人工智能、高性能雲計算以及可擴展及標準化的機器人自動化相結合的方式，為製藥及材料科學（包括農業技術、能源及新型化學品以及化妝品）等產業的全球和國內公司提供藥物及材料科學研發解決方案及服務。